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Abstract
Context: Trigeminal nerve stimulation (TNS) is a promising non-invasive brain stimulation intervention. The TNS has been proposed for major
depressive disorder (MDD) with auspicious results. The aim of this study was to review the literature on TNS for MDD.
Evidence Acquisition: Systematic review, using MEDLINE and EMBASE, of first articles available until 22nd of April 2016.
Results: We included seven studies; six of them were open-label studies and one sham-controlled randomized double-blinded trial. Most studies
had small sample sizes. Two studies were on MDD with comorbid posttraumatic stress disorder and one study focused on the elderly population.
Two different protocols of stimulation were reported. Studies had interesting positive results for treating MDD.
Conclusions: The TNS was reported to be well tolerated, with no severe adverse effect reported, and had impressive results for MDD. This promising,
safe and easy-to-use new neuromodulation technique could be a useful tool for MDD treatment. However, the results reported in the studies per-
formed so far must be analyzed under the strict limitations of the study design. Most of the studies on TNS are case studies or open-label trials with
very small sample sizes. We acknowledge that it is the time to initiate more rigorous sham-controlled trials to better understand the huge potential
involved with this technique, which could lead to the development of more accessible, easy-to-use, safe and non-invasive technology.
Keywords: Depression, Major Depressive Disorder, Trigeminal Nerve Stimulation, Cranial Nerve Stimulation,
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1. Context
Trigeminal nerve stimulation (TNS) is a novel neuro-
modulation technology, recently described for neurolog-
ical and psychiatric disorders such as epilepsy and ma-
jor depressive disorder (MDD). It is hypothesized that the
use of electrical stimulation over cranial nerves could
neuromodulate cortical and subcortical areas related to
neuropsychiatric disorders, such as the amygdala, insular
cortex, prefrontal cortex, hippocampus, thalamus, locus
coeruleus, nucleus of the solitary tract, and the anterior
cingulate cortex (1, 2), called the bottom-up mechanism, in
which the stimuli propagates from the cranial nerve in the
direction of the brainstem and central areas (3). The neu-
romodulatory effect of TNS over these areas has been eval-
uated for MDD in different protocols with interesting pos-
itive results. We hereby present a short-review on TNS for
MDD.
2. Evidence Acquisition
A systematic review according to the recommenda-
tions of the Cochrane group and to the PRISMA guidelines
was conducted (4). Two authors performed independent
systematic reviews and data extraction, and discrepancies
were resolved by consensus.
We reviewed the MEDLINE and EMBASE databases using
the key words: 1) “trigeminal nerve stimulation”, 2) “TNS”,
3) “trigeminal stimulation”, 4) “eTNS”, 6) “major depres-
sive disorder”, 7) “depression”, 8) “depressive disorder” and
9) “treatment-resistant depressive disorder”. The Boolean
terms were imputed: [(1) OR (2) OR (3) OR (4)] AND [(6) OR
(7) OR (8) OR (9)]. We searched for publications listed in
MEDLINE up to 22nd of April 2016.
2.1. Eligibility Criteria
We adopted the following inclusion criteria: 1)
Manuscript written in English 2) Randomized, sham-
controlled trials; 3) Provided data (on the manuscript or
upon request) for the estimation of the main outcomes,
i.e., mean (SD) values and response and remission rates.
We included series of cases, non-controlled trials and
randomized controlled trials. We excluded trials assessing
conditions other than MDD or interventions other than
TNS and case reports.
2.2. Data Extraction
The following variables were extracted according to a
structured checklist previously elaborated by the authors:
1) metadata (i.e., authorship, publication date, etc.); 2) de-
mographics (i.e., sample size in each group, age, gender); 3)
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characteristics of the TNS technique (i.e., frequency; inten-
sity; pulse duration; time period of stimulation; number
of sessions;); 4) study design (i.e. open-label study or ran-
domized sham-controlled study); 5) response and remis-
sion rates; 6) adverse effects and dropout rates.
3. Literature Review
Our systematic review yielded 35 studies after dupli-
cates were removed. Among them, 28 articles did not
match the eligibility criteria. Seven studies were included
(Table 1).
Stimulation protocols were divided into protocols I
and II. Both protocols had the following stimulation pa-
rameters: frequency of 120 Hz, asymmetrical alternate cur-
rent, pulse duration of 0.25 ms and intensity established
based on individual sensitivity and pain threshold. Stim-
ulation was delivered in order to achieve the sensitivity
threshold without causing pain. The first protocol was
performed during an eight-hour session, during sleep, for
eight weeks, with a 30 seconds on/30 seconds off cycle. The
second protocol was performed in 30-minute sessions, for
10 weekday sessions for two weeks, of continuous stimula-
tion.
The stimulation of the supraorbital branch of the
trigeminal nerve was at first described for treatment-
resistant epilepsy disorder patients by DeGiorgio and col-
laborators (5), with interesting results, and later evaluated
in a randomized controlled trial (6). The TNS was per-
formed at home, in an eight-hour session, during sleep and
for eight weeks, with improvements observed for refrac-
tory epilepsy. Following the studies on epilepsy, Schrader
(7) and colleagues (8) reported their findings firstly from a
pilot study with five patients with a mean age of 49.6 years
and later from an open-label trial with 12 patients that un-
derwent TNS by the nocturnal protocol for 55 sessions dur-
ing eight weeks with impressive positive results (response
rates of 75% and 54.5% in the HDRS-17, respectively). Follow-
ing these studies, Shiozawa and collaborators (9) investi-
gated the use of TNS for MDD with changes to the stimu-
lation protocol. The TNS was performed in 30-minute ses-
sions for ten sessions during two weeks. The on/off cycle
used in the previous studies was changed for a continuous
stimulation for 30 minutes. Firstly, an open-label trial was
performed (9) with 11 patients (mean age of 50.36 year) in
order to observe the effect of the reduced session of TNS
and the authors reported great results with the technique,
with a mean reduction of 5.72 points in HDRS-17, with all pa-
tients presenting a reduction of at least 50% of the depres-
sive symptoms and ten patients (90.9%) presenting remis-
sion of depressive symptoms as defined by less than eight
points in HDRS-17. In sequence, the same group conducted
a randomized, sham-controlled double-blinded study with
40 patients (mean age of 47.15) with 20 patients in each
group, performing the same 10-session protocol. The au-
thors reported that despite a great placebo effect, a differ-
ence of 6.36 points in HDRS-17 between the sham and the
active group was obtained (F = 6.38,df = 2, P = 0.0033) with
a maintenance of the clinical effect for one month after the
last day of stimulation.
Trevizol and colleagues later evaluated the safety and
efficacy for the elderly in an open-label trial with ten pa-
tients (mean age 73 years), reproducing the results ob-
served in younger patients, with 80% response rate and
40% of remission rate by the HDRS-17. The TNS was well tol-
erated with no severe adverse effects reported even for this
population. Due to common pathways involved in anxiety
symptoms, depressive symptoms and trauma-related dis-
orders, Cook et al. (10) and Trevizol et al. (11, 12) performed
studies on TNS for comorbid MDD and Posttraumatic Stress
Disorder with twelve and five patients, respectively. Both
groups reported their positive findings on depressive, anx-
iety and the core symptoms of Posttraumatic Stress Disor-
der (PTSD), enhancing the possibilities of uses in neuropsy-
chiatric disorders.
Following the hypothesis that subcortical and cortical
areas such as the amygdala, hippocampus, brainstem, lo-
cus coeruleus and nucleus of solitary tract could be stim-
ulated trough the trigeminal nerve transcutaneously, the
technique was used for the treatment of other neuropsy-
chiatric disorders such as panic disorder (13), generalized
anxiety disorder (14), irritable bowel syndrome (15), fi-
bromyalgia (16, 17), attention-deficit/hyperactivity disor-
der (18) and social anxiety disorder (19). The impact on
quantitative electroencephalography was reported in one
patient with MDD treated with TNS, with changes that cor-
related to the improvements in depressive symptoms (20).
The authors also reported one case of MDD during preg-
nancy with complete remission of depressive symptoms
without any pharmacological intervention, with no un-
wanted consequences for childbirth or newborns (21). The
TNS was reported to be a well-tolerated technique, with
no severe adverse effect reported, and to have impressive
results for MDD. Previous studies on the impact of TNS
on cognition reported no changes at cognitive evaluations
pre and post stimulation (22) and unlike what can be ob-
served with continuous current techniques such as tran-
scranial direct current stimulation, no skin lesions were
reported (23). This promising, safe and easy-to-use new
neuromodulation technique could be a useful tool for psy-
chiatric disorders treatment, given the positive results re-
ported so far on a variety of disorders.
However, the results reported in the studies performed
so far must be analyzed under the strict limitations of the
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Table 1. Study Characteristics from the Seven Trials Included in the Systematic Review
Study Study Design and
(No.)
Mean Age (SD) Percentage of Females Psychiatric
Comorbidities
TNS Protocol Results forMDD
Symptoms
Schrader, 2011 Open-Label Trial (5) 49.6 (10.9) 60% None I HDRS-28: response 75%
BDI: response 100%
Cook, 2013 Open-Label Trial (11) 48.1 (8.3) 63% None I HDRS-17: response 54,5%
and remission 36.4%
BDI: response 63.6%
Shiozawa, 2014 Open-Label Trial (11) 50.36 (11.8) 90.9% None II HDRS-17: response 100%
and remission 90.9%
Shiozawa, 2015 RCT (40) 47.15 (12.05) 65% None II Mean difference
between groups of -6.36
(F = 6.38,df = 2,
p=0.0033)
Trevizol, 2016 Open-Label Trial (10) 73 (7.4) 70% None II HDRS-17: 80% response
and 40% remission
Cook, 2016 Open-Label Trial (12) 52.8 (13.7) 66.6% PTSD I HDRS-17: 42% response
and 25%remission
Trevizol, 2016 Open-Label Trial (5) 41.6 (6.02) 80% PTSD II HDRS-17: 80% response
and 40% remission
Abbreviations: df, degrees of freedom; HDRS-17, 17-item hamilton depressive rating scale; MDD, major depressive disorder; No.,number of subjects included; PTSD, post-
traumatic stress disorder; RCT, randomized clinical trial; SD, standard deviation; TNS, trigeminal nerve stimulation.
study designs. Most of the studies on TNS are case stud-
ies or open-label trials with very small sample sizes and al-
though they evaluate TNS for many psychiatric disorders,
most of them have very similar symptoms, such as PTSD,
panic disorder, fibromyalgia, MDD and GAD. Regarding the
limitations here and the potential benefits of TNS, we ac-
knowledge that it is time to initiate more rigorous sham-
controlled trials to better understand the huge potential
involved with this technique, which could lead to the de-
velopment of accessible, easy-to-use, safe, and non-invasive
technology.
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